Single‐dose new insulin glargine 300 <scp>U/ml</scp> provides prolonged, stable glycaemic control in <scp>J</scp> apanese and <scp>E</scp> uropean people with type 1 diabetes

Abstract

Single-dose injections of Gla-300 present more constant and prolonged PK and PD profiles compared with Gla-100, maintaining blood glucose control for up to 36 h in euglycaemic clamp settings in Japanese and European participants with type 1 diabetes.